Streetbeat News

Price Targets

TTWO

Truist Securities analyst Matthew Thornton has reiterated a 'Buy' rating on Take-Two Interactive (NASDAQ:TTWO) and maintained a price target of $158.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 3:53 pm

TME

B of A Securities analyst Lei Zhang maintains a 'Buy' rating on Tencent Music Enter Gr (NYSE:TME) but lowers the price target from $10 to $8.8.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2023 | 3:51 pm

RSKD

Truist Securities analyst Terry Tillman has reiterated a 'Buy' rating on Riskified (NYSE:RSKD) and maintained a price target of $7.5.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 3:50 pm

DOC

Truist Securities analyst Michael Lewis has reiterated a 'Hold' rating on Physicians Realty Trust (NYSE:DOC) and maintained a price target of $15.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 3:49 pm

PTCT

Truist Securities analyst Barry Jonas has reiterated a 'Buy' rating on PTC Therapeutics (NASDAQ:PTCT) and maintained a price target of $65.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 3:49 pm

OXY

Truist Securities analyst Neal Dingmann has reiterated a 'Buy' rating on Occidental Petroleum (NYSE:OXY) and maintained a price target of $80.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 3:48 pm

IMVT

Truist Securities analyst Robyn Karnauskas has reiterated a 'Buy' rating on Immunovant (NASDAQ:IMVT) and maintained a $30 price target.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 3:47 pm

FATE

Truist Securities analyst Robyn Karnauskas has reiterated a 'Hold' rating on Fate Therapeutics (NASDAQ:FATE) and maintained a price target of $7.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 3:45 pm

ARVN

Truist Securities analyst Joon Lee has reiterated a 'Buy' rating on Arvinas (NASDAQ:ARVN) and maintained a price target of $65.

Portfolio Pulse from richadhand@benzinga.com

August 16, 2023 | 3:44 pm

EL

RBC Capital analyst Nik Modi has maintained an 'Outperform' rating on Estee Lauder Cos (NYSE:EL) but lowered the price target from $265 to $195.

Portfolio Pulse from Benzinga Newsdesk

August 16, 2023 | 3:43 pm